| abstract |
The present invention provides a TGR5 receptor agonist comprising a fused ring compound represented by the formula n nwherein ring A is an optionally substituted aromatic ring; and ring B′ is a 5- to 8-membered ring having one or more substituents or a salt thereof or a prodrug thereof, which is useful for the treatment of various diseases. |